[Form 3] Lixte Biotechnology Holdings, Inc. Warrants Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Peter Stazzone filed a Form 3 reporting an initial statement of beneficial ownership for Lixte Biotechnology Holdings, Inc. (symbol shown as LIXT) related to an event on 09/01/2025. The filing identifies Mr. Stazzone as an officer with the title Chief Financial Officer and indicates the form was filed by one reporting person. The Form 3 states no securities are beneficially owned by the reporting person. The filing is signed and dated 09/04/2025.

Insights

Securities Compliance Analyst

TL;DR: Routine Form 3 filing showing no securities owned by the newly reported officer.

This is a standard initial Section 16 filing where the reporting person discloses their relationship to the issuer and reports ownership (or lack thereof). The Form 3 names the reporting person as Chief Financial Officer and indicates no direct or indirect beneficial ownership of the issuer's securities at the time of the filing. From a compliance perspective, the filing meets basic disclosure elements: reporter identity, relationship, event date, and signature date.

Corporate Governance Expert

TL;DR: Disclosure is routine and non-material absent any ownership or additional transactions.

The filing documents an officer-level relationship without any reported holdings, which is informational but not material by itself. It establishes an audit trail for future Section 16 reporting obligations should the officer acquire or dispose of securities. No transactions, grants, or derivative positions are disclosed here.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Stazzone Peter

(Last) (First) (Middle)

680 E. COLORADO BOULEVARD, SUITE 180

(Street)

PASADENA CA 91101

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/01/2025

3. Issuer Name and Ticker or Trading Symbol
LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Peter Stazzone	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 3 filed by Peter Stazzone for LIXT report?

The Form 3 reports the reporting person's identity and relationship as Chief Financial Officer and states no securities are beneficially owned as of the filing.

When is the event date listed on the Form 3 for Lixte Biotechnology?

The Date of Event Requiring Statement shown on the Form 3 is 09/01/2025.

Was the Form 3 filed jointly or by a single reporting person?

The filing indicates the Form was filed by one reporting person.

Does the Form 3 disclose any derivative or stock option holdings for the reporting person?

No. The Form 3 explicitly states no securities are beneficially owned and lists no derivative securities or underlying shares.

When was the Form 3 signed?

The Form 3 is signed by Peter Stazzone and dated 09/04/2025.